| Radiologically isolated syndrome: 5-year risk for an initial clinical event DT Okuda, A Siva, O Kantarci, M Inglese, I Katz, M Tutuncu, BM Keegan, ... PloS one 9 (3), e90509, 2014 | 353 | 2014 |
| Quantifying the local tissue volume and composition in individual brains with magnetic resonance imaging A Mezer, JD Yeatman, N Stikov, KN Kay, NJ Cho, RF Dougherty, ML Perry, ... Nature medicine 19 (12), 1667-1672, 2013 | 321 | 2013 |
| Anteroposterior somatotopy of innocuous cooling activation focus in human dorsal posterior insular cortex LH Hua, IA Strigo, LC Baxter, SC Johnson, AD Craig American Journal of Physiology-Regulatory, Integrative and Comparative …, 2005 | 146 | 2005 |
| Ageing and multiple sclerosis JS Graves, KM Krysko, LH Hua, M Absinta, RJM Franklin, BM Segal The Lancet Neurology 22 (1), 66-77, 2023 | 80 | 2023 |
| Discontinuation of disease-modifying therapy in patients with multiple sclerosis over age 60 LH Hua, TH Fan, D Conway, N Thompson, TG Kinzy Multiple Sclerosis Journal 25 (5), 699-708, 2019 | 79 | 2019 |
| Therapeutic targets for multiple sclerosis: current treatment goals and future directions AL Smith, JA Cohen, LH Hua Neurotherapeutics 14 (4), 952-960, 2017 | 62 | 2017 |
| Dimethyl fumarate delays multiple sclerosis in radiologically isolated syndrome DT Okuda, O Kantarci, C Lebrun‐Frénay, MP Sormani, CJ Azevedo, ... Annals of neurology 93 (3), 604-614, 2023 | 49 | 2023 |
| A case of Susac syndrome with cervical spinal cord involvement on MRI LH Hua, SL Donlon, DT Okuda Journal of the neurological sciences 337 (1-2), 228-231, 2014 | 33 | 2014 |
| Thoracic spinal cord lesions are influenced by the degree of cervical spine involvement in multiple sclerosis LH Hua, SL Donlon, MJ Sobhanian, SM Portner, DT Okuda Spinal Cord 53 (7), 520-525, 2015 | 32 | 2015 |
| The two sides of siponimod: evidence for brain and immune mechanisms in multiple sclerosis SL Cohan, RHB Benedict, BAC Cree, J DeLuca, LH Hua, J Chun CNS drugs 36 (7), 703-719, 2022 | 28 | 2022 |
| Re-Evaluating the Use of IFN-β and Relapsing Multiple Sclerosis: Safety, Efficacy and Place in Therapy CH Goldschmidt, LH Hua Degenerative Neurological and Neuromuscular Disease 10, 29, 2020 | 23 | 2020 |
| Changes in patient-reported outcomes between continuers and discontinuers of disease modifying therapy in patients with multiple sclerosis over age 60 LH Hua, H Harris, D Conway, NR Thompson Multiple sclerosis and related disorders 30, 252-256, 2019 | 22 | 2019 |
| Clinical characteristics of a large multi-center cohort of people with multiple sclerosis over age 60 LH Hua, CM Hersh, F Tian, EM Mowry, KC Fitzgerald Multiple sclerosis and related disorders 47, 102637, 2021 | 21 | 2021 |
| The Impact of Price Reductions After Loss of Exclusivity in a Cost-Effectiveness Analysis: Fingolimod Versus Interferon Beta-1a for the Treatment of Relapsing-Remitting … LH Hua, CM Hersh, P Morten, J Kusel, F Lin, J Cave, S Varga, V Herrera, ... Journal of managed care & specialty pharmacy 25 (4), 490-498, 2019 | 18 | 2019 |
| Ten-year trends of palliative care utilization associated with multiple sclerosis patients in the United States from 2005 to 2014 YJ Lee, JW Yoo, L Hua, PC Kim, SJ Kim, JJ Shen Journal of Clinical Neuroscience 58, 13-19, 2018 | 17 | 2018 |
| Cognition and disease characteristics in adult onset versus late onset multiple sclerosis R Butler Pagnotti, LH Hua, JB Miller Multiple Sclerosis Journal 28 (6), 933-941, 2022 | 14 | 2022 |
| Effect of switching from natalizumab to moderate-vs high-efficacy DMT in clinical practice CM Hersh, H Harris, D Conway, LH Hua Neurology: Clinical Practice 10 (6), e53-e65, 2020 | 13 | 2020 |
| Gender Inequities in the Multiple Sclerosis Community: A Call for Action. E Waubant, L Amezcua, N Sicotte, K Hellwig, L Krupp, ... Annals of Neurology 84 (6), 958-959, 2018 | 10 | 2018 |
| The CELLO trial: Protocol of a planned phase 4 study to assess the efficacy of Ocrelizumab in patients with radiologically isolated syndrome EE Longbrake, LH Hua, EM Mowry, SA Gauthier, E Alvarez, AH Cross, ... Multiple Sclerosis and Related Disorders 68, 104143, 2022 | 9 | 2022 |
| Considerations in the development of generic disease therapies for multiple sclerosis LH Hua, JA Cohen Neurology: Clinical Practice 6 (4), 369-376, 2016 | 9 | 2016 |
